In recent days, two U.S. pharmaceutical companies announced that their COVID-19 vaccines could be available by December. U.S.-based Pfizer, who partnered with the German-based BioNTech, said it has a 95 percent success rate during clinical trials. Biotechnology company Moderna also reported a vaccine with a 94.5 percent efficacy rate.
Neither drug has undergone peer review by independent experts. The federal Food and Drug Administration is expected to use emergency procedures to allow rapid general distribution to selected groups such as medical workers.
Read more at The Progressive.